Nonesterified Fatty Acids and Cardiovascular Mortality in Elderly Men with CKD
Open Access
- 1 April 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 10 (4) , 584-591
Abstract
Background and objectives Although nonesterified fatty acids (NEFAs) are essential as energy substrate for the myocardium, an excess of circulating NEFAs can be harmful. This study aimed to assess plausible relationships between serum NEFA and mortality due to cardiovascular disease (CVD) in individuals with CKD. Design, setting, participants, & measurements This was a prospective cohort study from the third examination cycle of the Uppsala Longitudinal Study of Adult Men, a population-based survey of 1221 elderly men aged 70–71 years residing in Uppsala, Sweden. Data collection took place during 1991–1995. All participants had measures of kidney function; this study investigated 623 (51.7%) of these patients with manifest CKD (defined as either eGFR2 or urine albumin excretion rate ≥20 µg/min). Follow-up for mortality was done from examination date until death or December 31, 2007. After a median follow-up of 14 years (interquartile range, 8–16.8), associations of NEFAs with mortality (related to all causes, CVD, ischemic heart disease [IHD], or acute myocardial infarction) were ascertained. Results The median serum NEFA was 14.1 mg/dl (interquartile range, 11.3–17.8). No association was found with measures of kidney function. Diabetes and serum triglycerides were the only multivariate correlates of NEFA. During follow-up, 453 participants died, of which 209 deaths were due to CVD, including 88 IHD deaths, with 41 attributed to acute myocardial infarction (AMI). In fully adjusted covariates, serum NEFA was an independent risk factor for all-cause mortality (hazard ratio [HR] per log2 increase, 1.22; 95% confidence interval [95% CI], 1.00 to 1.48) and CVD-related death (HR, 1.51; 95% CI, 1.15 to 1.99), including both IHD (HR, 1.51; 95% CI, 1.00 to 2.32) and AMI mortality (HR, 2.08; 95% CI, 1.09 to 3.98). Conclusions Elevated serum NEFA associated with CVD mortality, and particularly with mortality due to AMI, in a homogeneous population of older men with moderate CKD.Keywords
This publication has 46 references indexed in Scilit:
- Using the Bernoulli trial approaches for detecting ordered alternativesBMC Medical Research Methodology, 2013
- Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney diseaseClinical and Experimental Nephrology, 2013
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice GuidelineAnnals of Internal Medicine, 2013
- Nonesterified Fatty Acids and Risk of Sudden Cardiac Death in Older AdultsCirculation: Arrhythmia and Electrophysiology, 2012
- L carnitine in hemodialysis patientsHemodialysis International, 2012
- Obesity, insulin resistance and free fatty acidsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly menNephrology Dialysis Transplantation, 2011
- The use of levo-carnitine in children with renal disease: a review and a call for future studiesPediatric Nephrology, 2005
- Therapeutic Effects of l‐Carnitine and Propionyl‐l‐carnitine on Cardiovascular Diseases: A ReviewAnnals of the New York Academy of Sciences, 2004
- Physiological regulation of NEFA availability: lipolysis pathwayProceedings of the Nutrition Society, 2004